467
edits
Cardiac Pharmacology: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
|||
| Line 124: | Line 124: | ||
|- | |- | ||
!Drug | !Drug | ||
!Drugs that | !Drugs that ↑ drug action | ||
!Drugs that | !Drugs that ↓ drug action | ||
|- | |- | ||
!Digoxin | !Digoxin | ||
| Line 328: | Line 328: | ||
!Side Effects (Prevalence %) | !Side Effects (Prevalence %) | ||
|- | |- | ||
|colspan="5" | |colspan="5" bgcolor="#E6E6FA"|'''Anti-hypertensives''' | ||
|- | |- | ||
|rowspan="2"|Diuretics | |rowspan="2"|Diuretics | ||
| Line 407: | Line 405: | ||
|Nifedipine: 5-20mg 3 times daily | |Nifedipine: 5-20mg 3 times daily | ||
|- | |- | ||
|colspan="5" bgcolor="#E6E6FA"|'''Anti-Arrhythmics''' | |||
|- | |- | ||
|Class I (sodium channel blockers) | |Class I (sodium channel blockers) | ||
| Line 442: | Line 440: | ||
|62.5-125 µg daily | |62.5-125 µg daily | ||
|- | |- | ||
|colspan="5" bgcolor="#E6E6FA"|'''Anti-platelet Drugs''' | |||
|- | |- | ||
|rowspan="7"| | |rowspan="7"| | ||
| Line 474: | Line 472: | ||
|Dyspnoea (13.8%), haemorrhage, bruising; nausea (4.3%), vomiting, diarrhoea (3.7%), hypertension (3.8%), hypotension (3.2%), back pain (3.6%), abdominal pain, dyspepsia, gastritis, dizziness (4.5%), chest pain (3.7%), headache (6.5%), cough (4.9%), rash, pruritus, fatigue (3.2%), constipation, arrhythmias including atrial fibrillation (4.2%), paraesthesia, confusion, hyperuricaemia, raised serum creatinine (7.4%), vertigo.<cite>Esc37</cite><cite>Esc38</cite> | |Dyspnoea (13.8%), haemorrhage, bruising; nausea (4.3%), vomiting, diarrhoea (3.7%), hypertension (3.8%), hypotension (3.2%), back pain (3.6%), abdominal pain, dyspepsia, gastritis, dizziness (4.5%), chest pain (3.7%), headache (6.5%), cough (4.9%), rash, pruritus, fatigue (3.2%), constipation, arrhythmias including atrial fibrillation (4.2%), paraesthesia, confusion, hyperuricaemia, raised serum creatinine (7.4%), vertigo.<cite>Esc37</cite><cite>Esc38</cite> | ||
|- | |- | ||
|colspan="5" bgcolor="#E6E6FA"|'''Vitamin K Antagonists''' | |||
|- | |- | ||
| | | | ||
| Line 488: | Line 486: | ||
|valign="top"|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency) | |valign="top"|Haemorrhage, nausea, vomiting, diarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia, purpura, rash, ‘purple toes’, skin necrosis (increased risk in patients with protein C or protein S deficiency) | ||
|- | |- | ||
|colspan="5" bgcolor="#E6E6FA"|'''Lipid-Lowering Drugs''' | |||
|- | |- | ||
|rowspan="3"|Statins | |rowspan="3"|Statins | ||
| Line 506: | Line 504: | ||
|Hyperlipidaemias of types IIa, IIb, III, IV and V | |Hyperlipidaemias of types IIa, IIb, III, IV and V | ||
|Gemfibrozil: 0.9-1.2mg daily | |Gemfibrozil: 0.9-1.2mg daily | ||
|Gastro-intestinal | |Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity<cite>Esc43</cite> | ||
|- | |||
|Ezetimibe | |||
|Primary and familial hyper-cholesterolaemia | |||
|10mg once daily | |||
|Gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis<cite>Esc44</cite> | |||
|} | |||
==References== | ==References== | ||